Calprotectin, a Biomarker of COVID-19 Severity (CALPRO)
Key facts
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- Jan 2023
- Ended
- Jul 2024
- Type of study
- Interventional, 3 groups
- Treatments tested
- Blood samples
- Record updated
- 12 March 2026
- Why it stopped
- Abandonment of the study project
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Criteria for all groups:
- Adults ≥ 18 years
- Dated and signed inform consent *; * : written informed consent of relative (trusted person, close family) in case of emergency procedure, by default emergency inclusion notified in medical file and pursuance consent sought
- Affiliation with a social security scheme; Criteria for control group:
- Age-matched healthy donors; Criteria for chronic myeloid malignancies:
- A diagnosis of low or high-risk myelodysplastic syndromes according to the WHO 2016 classification
- A diagnosis of dysplastic or proliferative chronic myelomonocytic leukemia according to WHO 2016; Criteria for COVID-19 patients:
- Patients with a recent diagnosis (<7 days since first symptoms) of moderate or severe COVID-19
Who cannot take part
- Patients with COVID-19 infection and active cancer or a history of cancer within the last 6 months
- Patients with COVID-19 and severe comorbidities including cardiovascular or respiratory diseases, unbalanced diabetes, obesity (IMC >29)
- Pregnant women
- Minor patient or major under protection
- Patient on AME (state medical aid)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to provide new insights into the pathophysiology of emergency hematopoiesis detected in severe COVID-19 patients. The investigators aim to explore the ability of calprotectin to induce an immunosuppressive myeloid program at the hematopoietic stem and progenitor cell (HSPC) level, and to identify the receptor(s) involved in this effect. Since patients with a hematological malignancy demonstrate a very high propensity to develop a severe COVID-19, the investigators will explore how HSPCs collected from patients with a myeloid malignancy respond to calprotectin.
The 3 groups in the trial
- COVID-19 patients (group 1)Treatment being tested
Patients with a recent diagnosis (\<7 days since first symptoms) of moderate or severe COVID-19
Treatment: Blood samples
- Chronic myeloid malignancies (group 2)Treatment being tested
Adults with chronic myeloid malignancies including myelodysplastic syndromes with low risk MDS ; high risk MDS according to IPSS-R or with dysplastic or proliferative chronic myelomonocytic leukemia according to WHO2016
Treatment: Blood samples
- Control group (group 3)Other group
Age-matched healthy donors
Treatment: Blood samples
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Calprotectin Involvement in Emergency Hematopoiesis Observed in Severe COVID-19
- Record updated
- 12 March 2026